Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
WUXI BIO, Vertex Pharmaceuticals Sign License & Research Service Agreement for T-cell Engager
Recommend 4 Positive 4 Negative 1 |
||||
|
||||
|
WUXI BIO (02269.HK) has signed a license and research service agreement with Vertex Pharmaceuticals Incorporated (VRTX.US) for an innovative trispecific T-cell Engager (TCE) for the treatment of B-cell mediated autoimmune diseases, as announced by WUXI BIO. Under the agreement, Vertex will have exclusive global rights to develop and commercialize an innovative tri-specific TCE at the preclinical stage designed for the treatment of B-cell mediated autoimmune diseases. WUXI BIO will receive an upfront payment and is eligible to receive development, regulatory, and sales milestone payments, as well as royalty payments. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
